Roles of signaling pathways in drug resistance, cancer initiating cells and cancer progression and metastasis

Advances in Biological Regulation

Volumn 57, Issue , 2015, Pages 75-101

  McCubrey, James A ^a   Abrams, Stephen L ^a   Fitzgerald, Timothy L ^a   Cocco, Lucio ^b   Martelli, Alberto M ^b   Montalto, Giuseppe ^c   Cervello, Melchiorre ^d   Scalisi, Aurora ^e   Candido, Saverio ^f   Libra, Massimo ^f   Steelman, Linda S ^a  

^a EAST CAROLINA UNIVERSITY   (United States)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c UNIVERSITY OF PALERMO   (Italy)

^d CNR   (Italy)

^e ASP Catania   (Italy)

^f UNIVERSITY OF CATANIA   (Italy)

Author keywords

Breast cancer; Cancer stem cells; EGFR; ER; HER2; Hormonal therapy; Targeted therapy; Therapy resistance

Indexed keywords

TUMOR PROTEIN;

ANIMAL; BIOSYNTHESIS; CELL PROLIFERATION; CELL TRANSFORMATION; DRUG RESISTANCE; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MALE; METABOLISM; METASTASIS; NEOPLASM; PATHOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; NEOPLASM METASTASIS; NEOPLASM PROTEINS; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84920836558     PISSN: 22124926     EISSN: None     Source Type: Book Series    
DOI: 10.1016/j.jbior.2014.09.016     Document Type: Review

References (141)

1. Abd El-Rehim D.M., Pinder S.E., Paish C.E., Bell J.A., Rampaul R.S., Blamey R.W. Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma. Br J Cancer 2004, 91:1532-1542.
2. Aleskandarany M.A., Rakha E.A., Ahmed M.A., Powe D.G., Paish E.C., Macmillan R.D., et al. PIK3CA expression in invasive breast cancer: a biomarker of poor prognosis. Breast Cancer Res Treat 2010, 122:45-53.
3. Barker C.J., Leibiger I.B., Berggren P.O. The pancreatic islet as a signaling hub. Adv Biol Regul 2013, 53:156-163.
4. Baselga J., Cortés J., Kim S.B. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. NEngl J Med 2012, 366:109-119. the CLEOPATRA Study Group.
5. Berns K., Horlings H.M., Hennessy B.T., Madiredjo M., Hijmans E.M., Beelen K., et al. Afunctional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007, 12:395-402.
6. Bertrand F.E., McCubrey J.A., Angus C.W., Nutter J.M., Sigounas G. NOTCH and PTEN in prostate cancer. Adv Biol Regul 2014, 56:51-65. pii:S2212-4926(14)00008-6. 10.1016/j.jbior.2014.05.002.
7. Bhargava R., Gerald W.L., Li A.R., Pan Q., Lal P., Ladanyi M., et al. EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations. Mod Pathol 2005, 18:1027-1033.
8. Blumenthal G.M., Scher N.S., Cortazar P., Chattopadhyay S., Tang S., Song P., et al. First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer. Clin Cancer Res 2013, 19:4911-4916.
9. Boultwood J., Yip B.H., Vuppusetty C., Pellagatti A., Wainscoat J.S. Activation of the mTOR pathway by the amino acid (L)-leucine in the 5q-syndrome and other ribosomopathies. Adv Biol Regul 2013, 53:8-17.
10. Carpenter G. ErbB-4: mechanism of action and biology. Exp Cell Res 2003, 284:66-77.
11. Carvalho S., Milanezi F., Costa J.L., Amendoeira I., Schmitt F. PIKing the right isoform: the emergent role of the p110beta subunit in breast cancer. Virchows Arch 2010, 456:235-243.
12. Chakrabarty A., Bhola N.E., Sutton C., Ghosh R., Kuba M.G., Dave B., et al. Trastuzumab-resistant cells rely on a HER2-PI3K-FoxO-survivin axis and are sensitive to PI3K inhibitors. Cancer Res 2013, 73:1190-1200.
13. Chan J.J., Flatters D., Rodrigues-Lima F., Yan J., Thalassinos K., Katan M. Comparative analysis of interactions of RASSF1-10. Adv Biol Regul 2013, 53:190-201.
14. Chan J.J., Katan M. PLCe and the RASSF family in tumour suppression and other functions. Adv Biol Regul 2013, 53:258-279.
15. Chappell W.H., Abrams S.L., Stadelman K.M., LaHair M.M., Franklin R.A., Cocco L., et al. Increased NGAL (Lnc2) expression after chemotherapeutic drug treatment. Adv Biol Regul 2013, 53:146-155.
16. Cizkova M., Susini A., Vacher S., Cizeron-Clairac G., Andrieu C., Driouch K., et al. PIK3CA mutation impact on survival in breast cancer patients and in ERα, PR and ERBB2-based subgroups. Breast Cancer Res 2012, 14:R28.
17. Cizkova M., Dujaric M.E., Lehmann-Che J., Scott V., Tembo O., Asselain B., et al. Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with trastuzumab. Br J Cancer 2013, 108:1807-1809.
18. Creighton C.J., Fu X., Hennessy B.T., Casa A.J., Zhang Y., Gonzalez-Angulo A.M., et al. Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer. Breast Cancer Res 2010, 12:R40. 10.1186/bcr2594.
19. Cufi S., Corominas-Faja B., Vazquez-Martin A., Oliveras-Ferraros C., Dorca J., Bosch-Barrera J., et al. Metformin-induced preferential killing of breast cancer initiating CD44+CD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts. Oncotarget 2012, 3:395-398.
20. Davis N.M., Sokolosky M., Stadelman K., Abrams S.L., Libra M., Candido S., et al. Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention. Oncotarget 2014, 5:4603-4650.
21. Del Vecchio C.A., Jensen K.C., Nitta R.T., Shain A.H., Giacomini C., Wong A.J. Epidermal growth factor receptor variant III contributes to cancer stem cell phenotypes in invasive breast carcinoma. Cancer Res 2012, 72:2657-2671.
22. Deng X.S., Wang S., Deng A., Liu B., Edgerton S.M., Lind S.E., et al. Metformin targets Stat3 to inhibit cell growth and induce apoptosis in triple-negative breast cancers. Cell Cycle 2012, 11:367-376.
23. Dorritie K.A., McCubrey J.A., Johnson D.E. STAT transcription factors in hematopoiesis and leukemogenesis: opportunities for therapeutic intervention. Leukemia 2014, 28:248-257.
24. Dorritie K.A., Redner R.L., Johnson D.E. STAT transcription factors in normal and cancer stem cells. Adv Biol Regul 2014, pii: S2212-4926(14) 00025-6.
25. Eckert L.B., Repasky G.A., Ulkü A.S., McFall A., Zhou H., Sartor C.I., et al. Involvement of Ras activation in human breast cancer cell signaling, invasion, and anoikis. Cancer Res 2004, 64:4585-4592.
26. Edwards J., Traynor P., Munro A.F., Pirret C.F., Dunne B., Bartlett J.M. The role of HER1-HER4 and EGFRvIII in hormone-refractory prostate cancer. Clin Cancer Res 2006, 12:123-130.
27. Elong Edimo W., Schurmans S., Roger P.P., Erneux C. SHIP2 signaling in normal and pathological situations: its impact on cell proliferation. Adv Biol Regul 2014, 54:142-151.
28. Elong Edimo W., Vanderwinden J.M., Erneux C. SHIP2 signalling at the plasma membrane, in the nucleus and at focal contacts. Adv Biol Regul 2013, 53:28-37.
29. Esteva F.J., Franco S.X., Hagan M.K., Brewster A.M., Somer R.A., Williams W., et al. An open-label safety study of lapatinib plus trastuzumab plus paclitaxel in first-line HER2-positive metastatic breast cancer. Oncologist 2013, 18:661-666.
30. Fitzgerald T.L., McCubrey J.A. Pancreatic cancer stem cells: association with cell surface markers, prognosis, resistance, metastasis and treatment. Adv Biol Regul 2014, 56:45-50. pii: S2212-4926(14)00007-4. 10.1016/j.jbior.2014.05.001.
31. Fragoso R., Barata J.T. PTEN and leukemia stem cells. Adv Biol Regul 2014, 56:22-29. pii: S2212-4926(14)00026-8. 10.1016/j.jbior.2014.05.005.
32. Ge H., Gong X., Tang C.K. Evidence of high incidence of EGFRvIII expression and coexpression with EGFR in human invasive breast cancer by laser capture microdissection and immunohistochemical analysis. Int J Cancer 2002, 98:357-361.
33. Generali D., Fox S.B., Brizzi M.P., Allevi G., Bonardi S., Aguggini S., et al. Down-regulation of phosphatidylinositol 3'-kinase/AKT/molecular target of rapamycin metabolic pathway by primary letrozole-based therapy in human breast cancer. Clin Cancer Res 2008, 14:2673-2680.
34. Generali D., Leek R., Fox S.B., Moore J.W., Taylor C., Chambers P., et al. EGFR mutations in exons 18-21 in sporadic breast cancer. Ann Oncol 2007, 18:203-205.
35. Gilmour L.M., Macleod K.G., McCaig A., Gullick W.J., Smyth J.F., Langdon S.P. Expression of erbB-4/HER-4 growth factor receptor isoforms in ovarian cancer. Cancer Res 2001, 61:2169-2176.
36. Han M., Liu M., Wang Y., Chen X., Xu J., Sun Y., et al. Antagonism of miR-21 reverses epithelial-mesenchymal transition and cancer stem cell phenotype through AKT/ERK1/2 inactivation by targeting PTEN. PLoS One 2012, 7:e39520.
37. Hennessy B.T., Gonzalez-Angulo A.M., Stemke-Hale K., Gilcrease M.Z., Krishnamurthy S., Lee J.S., et al. Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res 2009, 69:4116-4124.
38. Holbro T., Beerli R.R., Maurer F., Koziczak M., Barbas C.F., Hynes N.E. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci U S A 2003, 100:8933-8938.
39. Hollestelle A., Elstrodt F., Nagel J.H., Kallemeijn W.W., Schutte M. Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines. Mol Cancer Res 2007, 5:195-201.
40. Hongu T., Kanaho Y. Activation machinery of the small GTPase Arf6. Adv Biol Regul 2014, 54:59-66.
41. Hsieh A.C., Moasser M.M. Targeting HER proteins in cancer therapy and the role of the non-target HER3. Br J Cancer 2007, 97:453-457.
42. Hunt T. On the regulation of protein phosphatase 2A and its role in controlling entry into and exit from mitosis. Adv Biol Regul 2013, 53:173-178.
43. Ithimakin S., Day K.C., Malik F., Zen Q., Dawsey S.J., Bersano-Begey T.F., et al. HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: implications for efficacy of adjuvant trastuzumab. Cancer Res 2013, 73:1635-1646.
44. Jackson C., Browell D., Gautrey H., Tyson-Capper A. Clinical significance of HER-2 splice variants in breast cancer progression and drug resistance. Int J Cell Biol 2013, 973584. Epub 2013 Jul 1. 10.1155/2013/973584.
45. Jhanwar-Uniyal M., Jeevan D., Neil J., Shannon C., Albert L., Murali R. Deconstructing mTOR complexes in regulation of glioblastoma multiforme and its stem cells. Adv Biol Regul 2013, 53:202-210.
46. Jones F.E. HER4 intracellular domain (4ICD) activity in the developing mammary gland and breast cancer. JMammary Gland Biol Neoplasia 2008, 13:247-258.
47. Joo W.D., Visintin I., Mor G. Targeted cancer therapy - are the days of systemic chemotherapy numbered?. Maturitas 2013, pii: S0378-5122(13) 00292-2.
48. Jung J.W., Park S.B., Lee S.J., Seo M.S., Trosko J.E., Kang K.S. Metformin represses self-renewal of the human breast carcinoma stem cells via inhibition of estrogen receptor-mediated OCT4 expression. PLoS ONE 2011, 6:e28068.
49. Kancha R.K., von Bubnoff N., Bartosch N., Peschel C., Engh R.A., Duyster J. Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib. PLoS One 2011, 6:e26760. Epub 2011 Oct 28. 10.1371/journal.pone.0026760.
50. Keating G.M. Pertuzumab: in the first-line treatment of HER2-positive metastatic breast cancer. Drugs 2012, 72:353-360.
51. Kenney J.W., Moore C.E., Wang X., Proud C.G. Eukaryotic elongation factor 2 kinase, an unusual enzyme with multiple roles. Adv Biol Regul 2014, 55:15-27.
52. Korkaya H., Wicha M.S. Selective targeting of cancer stem cells: a new concept in cancer therapeutics. BioDrugs 2007, 21:299-310.
53. Korkaya H., Paulson A., Iovino F., Wicha M.S. HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion. Oncogene 2008, 27:6120-6130.
54. Korkaya H., Paulson A., Charafe-Jauffret E., Ginestier C., Brown M., Dutcher J., et al. Regulation of mammary stem/progenitor cells by PTEN/Akt/beta-catenin signaling. PLoS Biol 2009, 7(6):e1000121. 10.1371/journal.pbio.1000121.
55. Korkaya H., Wicha M.S. HER-2, notch, and breast cancer stem cells: targeting an axis of evil. Clin Cancer Res 2009, 15:1845-1847.
56. Korkaya H., Wicha M.S. Breast cancer stem cells: we've got them surrounded. Clin Cancer Res 2013, 19:511-513.
57. Korkaya H., Wicha M.S. HER2 and breast cancer stem cells: more than meets the eye. Cancer Res 2013, 73:3489-3493.
58. Kümler I., Tuxen M.K., Nielsen D.L. Asystematic review of dual targeting in HER2-positive breast cancer. Cancer Treat Rev 2013, pii: S0305-7372(13) 00191-6.
59. Lattanzio R., Piantelli M., Falasca M. Role of phospholipase C in cell invasion and metastasis. Adv Biol Regul 2013, 53:309-318.
60. Laurent P.A., Severin S., Gratacap M.P., Payrastre B. Class I PI 3-kinases signaling in platelet activation and thrombosis: PDK1/Akt/GSK3 axis and impact of PTEN and SHIP1. Adv Biol Regul 2014, 54:162-174.
61. Lee C.M., Shrieve D.C., Zempolich K.A., Lee R.J., Hammond E., Handrahan D.L., et al. Correlation between human epidermal growth factor receptor family (EGFR, HER2, HER3, HER4), phosphorylated Akt (P-Akt), and clinical outcomes after radiation therapy in carcinoma of the cervix. Gynecol Oncol 2005, 99:415-421.
62. Loi S., Haibe-Kains B., Majjaj S., Lallemand F., Durbecq V., Larsimont D., et al. PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer. Proc Natl Acad Sci U S A 2010, 107:10208-10213.
63. Maertens O., Cichowski K. An expanding role for RAS GTPase activating proteins (RAS GAPs) in cancer. Adv Biol Regul 2014, 55.
64. Malik F., Korkaya H., Clouthier S.G., Wicha M.S. Lin28 and HER2: two stem cell regulators conspire to drive aggressive breast cancer. Cell Cycle 2012, 11:2780-2781.
65. Martelli A.M., Evangelisti C., Chappell W., Abrams S.L., Bäsecke J., Stivala F., et al. Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway. Leukemia 2011, 25:1064-1079.
66. Martelli A.M., Buontempo F., Evangelisti C. GSK-3β: a key regulator of breast cancer drug resistance. Cell Cycle 2014, 13:697-698.
67. Martelli A.M., Lonetti A., Buontempo F., Ricci F., Tazzari P.L., Evangelisti C., et al. Targeting signaling pathways in T-cell acute lymphoblastic leukemia initiating cells. Adv Biol Regul 2014, 56:6-21. pii: S2212-4926(14)00006-2. 10.1016/j.jbior.2014.04.004.
68. Martin-Castillo B., Oliveras-Ferraros C., Vazquez-Martin A., Cufí S., Moreno J.M., Corominas-Faja B., et al. Basal/HER2 breast carcinomas: integrating molecular taxonomy with cancer stem cell dynamics to predict primary resistance to trastuzumab (Herceptin). Cell Cycle 2013, 15(12):225-245.
69. McCormack P.L. Pertuzumab: a review of its use for first-line combination treatment of HER2-positive metastatic breast cancer. Drugs 2013, 73:1491-1502.
70. McCubrey J., Steelman L., Wang X., Algate P., Hoyle P., White C., et al. Differential-effects of viral and cellular oncogenes on the growth factor-dependency of hematopoietic-cells. Int J Oncol 1995, 7:295-310.
71. McCubrey J.A., Shelton J.G., Steelman L.S., Franklin R.A., Sreevalsan T., McMahon M. Effects of a conditionally active v-ErbB and an EGF-R inhibitor on transformation of NIH-3T3 cells and abrogation of cytokine dependency of hematopoietic cells. Oncogene 2004, 23:7810-7820.
72. McCubrey J.A., Sokolosky M.L., Lehmann B.D., Taylor J.R., Navolanic P.M., Chappell W.H., et al. Alteration of Akt activity increases chemotherapeutic drug and hormonal resistance in breast cancer yet confers an Achilles heel by sensitization to targeted therapy. Adv Enzyme Regul 2008, 48:113-135.
73. McCubrey J.A., Steelman L.S., Kempf C.R., Chappell W.H., Abrams S.L., Stivala F., et al. Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways. JCell Physiol 2011, 226:2762-2781.
74. McCubrey J.A., Cocco L. Foreword: "targeting signaling pathways in stem cells". Adv Biol Regul 2014, 56:1-5. pii: S2212-4926(14)00028-1. 10.1016/j.jbior.2014.07.001.
75. McCubrey J.A., Davis N.M., Abrams S.L., Montalto G., Cervello M., Basecke J., et al. Diverse roles of GSK-3: tumor promoter-tumor suppressor, target in cancer therapy. Adv Biol Regul 2014, 54:176-196.
76. McCubrey J.A., Steelman L.S., Bertrand F.E., Davis N.M., Sokolosky M., Abrams S.L., et al. GSK-3 as potential target for therapeutic intervention in cancer. Oncotarget 2014, 5:2881-2911.
77. McCubrey J.A., Davis N.M., Abrams S.L., Montalto G., Cervello M., Libra M., et al. Targeting breast cancer initiating cells: advances in breast cancer research and therapy. Adv Biol Regul 2014, 56:81-107. pii: S2212-4926(14)00009-8. 10.1016/j.jbior.2014.05.003.
78. McCubrey J.A., Steelman L.S., Bertrand F.E., Davis N.M., Abrams S.L., Montalto G., et al. Multifaceted roles of GSK-3 and Wnt/β-catenin in hematopoiesis and leukemogenesis: opportunities for therapeutic intervention. Leukemia 2014, 28:15-33.
79. Meric-Bernstam F., Chen H., Akcakanat A., Do K.A., Lluch A., Hennessy B.T., et al. Aberrations in translational regulation are associated with poor prognosis in hormone receptor-positive breast cancer. Breast Cancer Res 2012, 14:R138.
80. Metzger-Filho O., Winer E.P., Krop I. Pertuzumab: optimizing HER2 blockade. Clin Cancer Res 2013, 19:5552-5556.
81. Milanezi F., Carvalho S., Schmitt F.C. EGFR/HER2 in breast cancer: a biological approach for molecular diagnosis and therapy. Expert Rev Mol Diagn 2008, 8:417-434.
82. Mill C.P., Zordan M.D., Rothenberg S.M., Settleman J., Leary J.F., Riese D.J. ErbB2 is necessary for ErbB4 ligands to stimulate oncogenic activities in models of human breast cancer. Genes Cancer 2011, 2:792-804.
83. Mill C.P., Gettinger K.L., Riese D.J. II Ligand stimulation of ErbB4 and A constitutively-active ErbB4 mutant result in different biological responses in human pancreatic tumor cell lines. Exp Cell Res 2011, 317:392-404.
84. Miller T.W., Hennessy B.T., González-Angulo A.M., Fox E.M., Mills G.B., Chen H., et al. Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer. JClin Invest 2010, 120:2406-2413.
85. Miller T.W., Pérez-Torres M., Narasanna A., Guix M., Stål O., Pérez-Tenorio G., et al. Loss of phosphatase and tensin homologue deleted on chromosome 10 engages ErbB3 and insulin-like growth factor-I receptor signaling to promote antiestrogen resistance in breast cancer. Cancer Res 2009, 69:4192-4201.
86. Miller T.W., Rexer B.N., Garrett J.T., Arteaga C.L. Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer. Breast Cancer Res 2011, 13:224. 10.1186/bcr3039.
87. Mukherjee D., Zhao J. The role of chemokine receptor CXCR4 in breast cancer metastasis. Am J Cancer Res 2013, 3:46-57.
88. Müller A., Homey B., Soto H., Ge N., Catron D., Buchanan M.E., et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001, 410:50-56.
89. Nahta R., Esteva F.J. HER-2-targeted therapy - lessons learned and future directions. Clin Cancer Res 2003, 9:5078-5084.
90. Nieto Y., Nawaz F., Jones R.B., Shpall E.J., Nawaz S. Prognostic significance of overexpression and phosphorylation of epidermal growth factor receptor (EGFR) and the presence of truncated EGFRvIII in locoregionally advanced breast cancer. JClin Oncol 2007, 25:4405-4413.
91. Oliveras-Ferraros C., Corominas-Faja B., Cufi S., Vazquez-Martin A., Martin-Castillo B., Iglesias J.M., et al. Epithelial-to-mesenchymal transition (EMT) confers primary resistance to trastuzumab (Herceptin). Cell Cycle 2012, 11:4020-4032.
92. O'Loughlin C., Heenan M., Coyle S., Clynes M. Altered cell cycle response of drug-resistant lung carcinoma cells to doxorubicin. Eur J Cancer 2000, 36:1149-1160.
93. Paik S., Kim C., Wolmark N. HER2 status and benefit from adjuvant trastuzumab in breast cancer. NEngl J Med 2008, 358:1409-1411.
94. Pawlowski V., Révillion F., Hebbar M., Hornez L., Peyrat J.P. Prognostic value of the type I growth factor receptors in a large series of human primary breast cancers quantified with a real-time reverse transcription-polymerase chain reaction assay. Clin Cancer Res 2000, 6:4217-4225.
95. Pitfield S.E., Bryant I., Penington D.J., Park G., Riese D.J. Phosphorylation of ErbB4 on tyrosine 1056 is critical for ErbB4 coupling to inhibition of colony formation by human mammary cell lines. Oncol Res 2006, 16:179-193.
96. Pouillon V., Marechal Y., Frippiat C., Erneux C., Schurmans S. Inositol 1,4,5-trisphosphate 3-kinase B (Itpkb) controls survival, proliferation and cytokine production in mouse peripheral T cells. Adv Biol Regul 2013, 53:39-50.
97. Rae J.M., Scheys J.O., Clark K.M., Chadwick R.B., Kiefer M.C., Lippman M.E. EGFR and EGFRvIII expression in primary breast cancer and cell lines. Breast Cancer Res Treat 2004, 87:87-95.
98. Rahimi M., George J., Tang C. EGFR variant-mediated invasion by enhanced CXCR4 expression through transcriptional and post-translational mechanisms. Int J Cancer 2010, 126:1850-1860.
99. Rahimi M., Toth T.A., Tang C.K. CXCR4 suppression attenuates EGFRvIII-mediated invasion and induces p38 MAPK-dependent protein trafficking and degradation of EGFRvIII in breast cancer cells. Cancer Lett 2011, 306:43-51.
100. Raven J.F., Williams V., Wang S., Tremblay M.L., Muller W.J., Durbin J.E., et al. Stat1 is a suppressor of ErbB2/Neu-mediated cellular transformation and mouse mammary gland tumor formation. Cell Cycle 2011, 10:794-804.
101. Reis-Filho J.S., Milanezi F., Carvalho S., Simpson P.T., Steele D., Savage K., et al. Metaplastic breast carcinomas exhibit EGFR, but not HER2, gene amplification and overexpression: immunohistochemical and chromogenic in situ hybridization analysis. Breast Cancer Res 2005, 7:R1028-R1035.
102. Reis-Filho J.S., Pinheiro C., Lambros M.B., Milanezi F., Carvalho S., Savage K., et al. EGFR amplification and lack of activating mutations in metaplastic breast carcinomas. JPathol 2006, 209:445-453.
103. Rexer B.N., Ham A.J., Rinehart C., Hill S., Granja-Ingram Nde M., Gonzalez-Angulo A.B., et al. Phosphoproteomic mass spectrometry profiling links Src family kinases to escape from HER2 tyrosine kinase inhibition. Oncogene 2011, 30:4163-4174.
104. Rexer B.N., Shyr Y., Arteaga C.L. Phosphatase and tensin homolog deficiency and resistance to trastuzumab and chemotherapy. JClin Oncol 2013, 31:2073-2075.
105. Ribeiro D., Melao A., Barata J.T. IL-7R-mediated signaling in T-cell acute lymphoblastic leukemia. Adv Biol Regul 2013, 53:211-222.
106. Saglam O., Shah V., Worsham M.J. Molecular differentiation of early and late stage laryngeal squamous cell carcinoma: an exploratory analysis. Diagn Mol Pathol 2007, 16:218-221.
107. Sanchez-Alvarez R., Martinez-Outschoorn U.E., Lamb R., Hulit J., Howell A., Gandara R., et al. Mitochondrial dysfunction in breast cancer cells prevents tumor growth: understanding chemoprevention with metformin. Cell Cycle 2013, 12:172-182.
108. Santarpia L., Qi Y., Stemke-Hale K., Wang B., Young E.J., Booser D.J., et al. Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers. Breast Cancer Res Treat 2012, 134:333-343.
109. Sendur M.A., Zengin N., Aksoy S., Altundag K. Everolimus: a new hope for patients with breast cancer. Curr Med Res Opin 2014, 30:75-87.
110. Shelton J.G., Moye P.W., Steelman L.S., Blalock W.L., Lee J.T., Franklin R.A., et al. Differential effects of kinase cascade inhibitors on neoplastic and cytokine-mediated cell proliferation. Leukemia 2003, 17:1765-1782.
111. Shelton J.G., Steelman L.S., Abrams S.L., White E.R., Akula S.M., Franklin R.A., et al. Conditional EGFR promotes cell cycle progression and prevention of apoptosis in the absence of autocrine cytokines. Cell Cycle 2005, 4:822-830.
112. Shiizaki S., Naguro I., Ichijo H. Activation mechanisms of ASK1 in response to various stresses and its significance in intracellular signaling. Adv Biol Regul 2013, 53:135-144.
113. Shostak K., Chariot A. NF-κB, stem cells and breast cancer: the links get stronger. Breast Cancer Res 2011, 13:214.
114. Silva H.A., Abraul E., Raimundo D., Dias M.F., Marques C., Guerra C., et al. Molecular detection of EGFRvIII-positive cells in the peripheral blood of breast cancer patients. Eur J Cancer 2006, 42:2617-2622.
115. Sokolosky M.L., Stadelman K.M., Chappell W.H., Abrams S.L., Martelli A.M., Stivala F., et al. Involvement of Akt-1 and mTOR in sensitivity of breast cancer to targeted therapy. Oncotarget 2011, 2:538-550.
116. Sokolosky M., Chappell W.H., Stadelman K., Abrams S.L., Davis N.M., Steelman L.S., et al. Inhibition of GSK-3β activity can result in drug and hormonal resistance and alter sensitivity to targeted therapy in MCF-7 breast cancer cells. Cell Cycle 2014, 13:820-833.
117. Steelman L.S., Navolanic P.M., Sokolosky M.L., Taylor J.R., Lehmann B.D., Chappell W.H., et al. Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors. Oncogene 2008, 27:4086-4095.
118. Steelman L.S., Navolanic P., Chappell W.H., Abrams S.L., Wong E.W.T., Martelli A.M., et al. Involvement of Akt and mTOR in chemotherapeutic- and hormonal-based drug resistance and response to radiation in breast cancer cells. Cell Cycle 2011, 10:3003-3015.
119. Stemke-Hale K., Gonzalez-Angulo A.M., Lluch A., Neve R.M., Kuo W.L., Davies M., et al. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res 2008, 68:6084-6091.
120. Sundvall M., Iljin K., Kilpinen S., Sara H., Kallioniemi O.P., Elenius K. Role of ErbB4 in breast cancer. JMammary Gland Biol Neoplasia 2008, 13:259-268.
121. Suo Z., Berner H.S., Risberg B., Karlsson M.G., Nesland J.M. Estrogen receptor-alpha and C-ERBB-4 expression in breast carcinomas. Virchows Arch 2001, 439:62-69.
122. Suo Z., Risberg B., Kalsson M.G., Willman K., Tierens A., Skovlund E., et al. c-erbB-2 and c-erbB-4 receptors have different effects on survival. JPathol 2002, 196:17-25.
123. Tang C.K., Concepcion X.Z., Milan M., Gong X., Montgomery E., Lippman M.E. Ribozyme-mediated down-regulation of ErbB-4 in estrogen receptor-positive breast cancer cells inhibits proliferation both invitro and invivo. Cancer Res 1999, 59:5315-5322.
124. Tang C.K., Gong X.Q., Moscatello D.K., Wong A.J., Lippman M.E. Epidermal growth factor receptor vIII enhances tumorigenicity in human breast cancer. Cancer Res 2000, 60:3081-3087.
125. Teicher B.A., Doroshow J.H. The promise of antibody-drug conjugates. NEngl J Med 2012, 367:1847-1848.
126. Teng Y.H., Tan W.J., Thike A.A., Cheok P.Y., Tse G.M., Wong N.S., et al. Mutations in the epidermal growth factor receptor (EGFR) gene in triple negative breast cancer: possible implications for targeted therapy. Breast Cancer Res 2011, 13:R35.
127. Thakkar J.P., Mehta D.G. Areview of an unfavorable subset of breast cancer: estrogen receptor positive progesterone receptor negative. Oncologist 2011, 16:276-285.
128. Thybusch-Bernhardt A., Beckmann S., Juhl H. Comparative analysis of the EGF-receptor family in pancreatic cancer: expression of HER-4 correlates with a favourable tumor stage. Int J Surg Investig 2001, 2:393-400.
129. Toker A., Marmiroli S. Signaling specificity in the Akt pathway in biology and disease. Adv Biol Regul 2014, 55:28-38.
130. Uberall I., Kolar Z., Trojanec R., Berkovcova J., Hajduch M. The status and role of ErbB receptors in human cancer. Exp Mol Pathol 2008, 84:79-89.
131. Verma S., Miles D., Gianni L., Krop I.E., Welslau M., Baselga J., et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. NEngl J Med 2012, 367:1783-1791.
132. Vicier C., Dieci M.V., Andre F. New strategies to overcome resistance to mammalian target of rapamycin inhibitors in breast cancer. Curr Opin Oncol 2013, 25:587-593.
133. Vidal G.A., Clark D.E., Marrero L., Jones F.E. Aconstitutively active ERBB4/HER4 allele with enhanced transcriptional coactivation and cell-killing activities. Oncogene 2007, 26:462-466.
134. Vinayak S., Carlson R.W. mTOR inhibitors in the treatment of breast cancer. Oncology 2013, 27:38-44.
135. Wang W.Z., Cheng J., Luo J., Zhuang S.M. Abrogation of G2/M arrest sensitizes curcumin-resistant hepatoma cells to apoptosis. FEBS Lett 2008, 582:2689-2695.
136. Weinstein-Oppenheimer C.R., Henríquez-Roldán C.F., Davis J., Navolanic P.M., Saleh O.A., Steelman L.S., et al. Role of the Raf signal transduction cascade in the invitro resistance to the anticancer drug doxorubicin. Clin Cancer Res 2001, 7:2892-2907.
137. Williams E.E., Trout L.J., Gallo R.M., Pitfield S.E., Bryant I., Penington D.J., et al. Aconstitutively active ErbB4 mutant inhibits drug-resistant colony formation by the DU-145 and PC-3 human prostate tumor cell lines. Cancer Lett 2003, 192:67-74.
138. Witton C.J., Reeves J.R., Going J.J., Cooke T.G., Bartlett J.M. Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. JPathol 2003, 200:290-297.
139. Yang S.X., Costantino J.P., Kim C., Mamounas E.P., Nguyen D., Jeong J.H., et al. Akt phosphorylation at Ser473 predicts benefit of paclitaxel chemotherapy in node-positive breast cancer. JClin Oncol 2010, 28:2974-2981.
140. Yu H., Gong X., Luo X., Han W., Hong G., Singh B., et al. Co-expression of EGFRvIII with ErbB-2 enhances tumorigenesis: EGFRvIII mediated constitutively activated and sustained signaling pathways, whereas EGF-induced a transient effect on EGFR-mediated signaling pathways. Cancer Biol Ther 2008, 7:1818-1828.
141. Zhang Y., Su H., Rahimi M., Tochihara R., Tang C. EGFRvIII-induced estrogen-independence, tamoxifen-resistance phenotype correlates with PgR expression and modulation of apoptotic molecules in breast cancer. Int J Cancer 2009, 125:2021-2028.